Skip to main content
    I

    InflaRx N.V. (IFRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.44
    -0.04 (-2.70%)

    Market Cap: $219.48M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    61%(22/36)
    Avg Surprise
    -13.76%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.05
    Range$-0.08 - $-0.03
    5 analysts
    EPS Revisions
    3
    0
    7d
    3
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.04-30.0%
    60d ago$-0.05+1.0%
    30d ago$-0.05+1.0%
    7d ago$-0.05+1.0%
    Current$-0.05
    Revenue Consensus
    $0
    Range$0 - $0
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.01
    Range$-0.05 - $0.01
    5 analysts
    Revenue Consensus
    $-9300
    Range$-9300 - $-9300
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.01---
    Sep 26EST
    		-$-0.05---
    Jun 26
    Reported Aug 6
    		$-0.11$-0.08-37.50%Miss+54.2%
    Mar 26
    Reported May 7
    		$-0.08N/A+55.56%Beat+38.5%
    Dec 25
    Reported Mar 19
    		$-0.15$-0.15+0.00%Beat-66.7%
    Sep 25
    Reported Nov 10
    		$-0.18$-0.12-50.00%Miss+40.0%
    Jun 25
    Reported Aug 7
    		$-0.24$-0.24+0.00%Beat+0.0%
    Mar 25
    Reported May 7
    		$-0.13$-0.18+27.78%Beat+23.5%
    Dec 24
    Reported Mar 20
    		$-0.09N/A+64.19%Beat+66.7%
    Sep 24
    Reported Nov 8
    		$-0.30$-0.25-20.00%Miss-130.8%
    Jun 24
    Reported Aug 8
    		$-0.24$-0.18-33.33%Miss-71.4%
    Mar 24
    Reported May 8
    		$-0.17$-0.22+22.73%Beat+32.0%
    Dec 23
    Reported Mar 21
    		$-0.27$-0.18-50.00%Miss-50.0%
    Sep 23
    Reported Nov 1
    		$-0.13$-0.23+43.48%Beat+27.8%
    Jun 23
    Reported Aug 10
    		$-0.14N/A+56.25%Beat-1500.0%
    Mar 23
    Reported May 11
    		$-0.25$-0.27+7.41%Beat+21.9%
    Dec 22
    Reported Mar 22
    		$-0.18$-0.25+28.00%Beat+43.8%
    Sep 22
    Reported Nov 9
    		$-0.18$-0.35+48.57%Beat+33.3%
    Jun 22
    Reported Aug 5
    		$0.01N/A+103.13%Beat+103.0%
    Mar 22
    Reported May 12
    		$-0.32$-0.34+5.88%Beat-77.8%
    Dec 21
    Reported Mar 24
    		$-0.32$-0.22-45.45%Miss+0.0%
    Sep 21
    Reported Nov 5
    		$-0.27$-0.34+20.59%Beat-8.0%
    Jun 21
    Reported Aug 5
    		$-0.33$-0.21-57.14%Miss+13.2%
    Mar 21
    Reported May 12
    		$-0.18$-0.22+18.18%Beat+43.8%
    Dec 20
    Reported Mar 25
    		$-0.32$-0.22-45.45%Miss+38.5%
    Sep 20
    Reported Oct 29
    		$-0.25$-0.33+24.24%Beat+55.4%
    Jun 20
    Reported Jul 30
    		$-0.38$-0.36-5.56%Miss+35.6%
    Mar 20
    Reported Apr 29
    		$-0.32$-0.52+38.46%Beat+15.8%
    Dec 19
    Reported Dec 31
    		$-0.52$-0.60+13.33%Beat-33.3%
    Sep 19
    Reported Nov 7
    		$-0.56$-0.54-3.70%Miss-86.7%
    Jun 19
    Reported Aug 14
    		$-0.59$-0.46-28.26%Miss-490.0%
    Mar 19
    Reported May 23
    		$-0.38$-0.51+25.49%Beat+5.0%
    Dec 18
    Reported Mar 28
    		$-0.39$-0.36-8.33%Miss+81.9%
    Sep 18
    Reported Nov 21
    		$-0.30$-0.33+9.09%Beat+99.8%
    Jun 18
    Reported Aug 9
    		$-0.10N/A+67.74%Beat+37.5%
    Mar 18
    Reported May 17
    		$-0.40$-0.28-42.86%Miss-
    Dec 17
    Reported Mar 29
    		$-2.16$-0.25-764.00%Miss-
    Sep 17
    Reported Nov 8
    		$-144.00$-171.38+15.98%Beat-
    Mar 17
    Reported May 4
    		$-0.16$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-2.38EV/EBITDAN/A
    Price/FCF-6.07xFCF Yield-16.47%
    Profitability
    Profit Margin0.00%Operating Margin352965.00%
    ROE-38.50%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-652.41x
    Current Ratio8.22xQuick Ratio8.22x
    Trading Statistics
    Beta2.61Avg Volume531.34K
    52-Week High$2.9552-Week Low$0.80

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.57
    SMA 20$1.75
    SMA 50$1.96
    SMA 200$1.61
    EMA 10$1.58
    EMA 20$1.71
    EMA 50$1.86
    EMA 200$1.70

    MACD

    Line: -0.15Signal: -0.12Hist: -0.02

    ADX

    ADX: 26.2+DI: 11.9-DI: 28.3

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down100.0
    PSAR$1.58

    Bollinger Bands

    Upper Band$2.17
    Lower Band$1.33
    %B Position4845%(Upper)
    Band Width0.14

    RSI (14-Day)

    Oversold
    25.4

    Momentum Oscillators

    Stoch %K6.5
    Stoch %D12.0
    Williams %R-98.1
    ROC (10d)-15.8%
    Momentum-0.27
    CCI (20d)-112.1
    MFI (14d)9.7

    Volatility Measures

    ATR (14d)$0.12(8.3%)
    StdDev (20d)0.21
    Hist Vol42.7%(High)

    Volume Flow

    VWAP$1.47
    OBV144.1M
    AD Line-40.8M
    CMF (20d)-0.479

    Volume Metrics

    Avg Vol (20d)510.5K
    Vol Ratio1.1x
    VWMA (20d)$1.71

    Pivot Points

    R3$1.60
    R2$1.57
    R1$1.52
    Pivot Point$1.49
    S1$1.45
    S2$1.42
    S3$1.37

    Advanced Oscillators

    TSI-39.02
    Ultimate Osc29.2
    KST-234.27

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$-33,931$23,830$39,432$0$-423$123,819$6,357$36,037$2,286$60,803
    Cost of Revenue$0$88,615$4.86M$333$2.40M$9,291$2.82M$-72,555$348,153$220,521$277,146$255,116
    Gross Profit$0$-88,615$-4,892,342$23,497$-2,360,151$-9,291$-2,821,343$196,374$-341,796$-184,484$-274,860$-194,313
    Operating Expenses$7.05M$7.21M$7.96M$9.50M$10.47M$13.00M$6.94M$15.56M$15.05M$12.30M$13.03M$10.96M
    R&D$4.74M$4.17M$5.26M$6.24M$7.20M$7.02M$6.91M$11.14M$10.02M$7.30M$8.07M$7.31M
    SG&A$2.55M$3.18M$4.56M$2.62M$3.70M$5.06M$5.67M$2.81M$3.50M$3.58M$4.17M$2.90M
    Operating Income$-7,051,045$-7,208,150$-12,856,841$-9,477,005$-12,825,155$-13,005,139$-9,763,471$-15,360,039$-15,396,663$-12,488,690$-13,306,235$-11,150,854
    Interest Income$770,661$334,768$391,309$438,134$522,221$493,764$674,338$768,326$848,243$908,426$1.07M$1.19M
    Interest Expense$14,643$15,052$15,890$14,359$3,355$4,086$4,779$5,032$8,732$5,027$21,671$0
    Income Before Tax$-10,648,484$-5,592,649$-10,642,392$-12,248,808$-14,323,438$-8,314,025$-5,111,772$-17,444,437$-12,691,014$-9,657,236$-15,930,157$-7,451,410
    Income Tax Expense$0$0$0$12,282$0$0$0$5,217$-1$2$-2$4,897
    Net Income$-10,648,484$-5,592,649$-10,642,393$-12,261,089$-14,416,271$-8,314,027$-5,111,772$-17,449,654$-13,845,741$-9,657,236$-15,930,156$-7,451,410
    EBITDA$-10,541,760$-5,490,658$-10,534,064$-12,134,656$-14,205,083$-8,196,138$-4,996,256$-17,327,960$-12,543,299$-9,528,655$-15,774,473$-7,307,593
    EBIT$-10,633,841$-5,577,840$-10,624,953$-12,234,449$-14,320,083$-8,309,939$-5,106,993$-17,439,405$-12,682,282$-9,652,604$-15,910,005$-7,446,513
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IFRX

    News

    InflaRx schedules kidney data: Needham targets InflaRx stock at USD 8.00

    InflaRx is preparing to present kidney data for its drug izicopan on October 22, 2026, a key clinical milestone. Needham initiated coverage with a "Buy" rating and an $8.00 price target for InflaRx stock...

    ad-hoc-news.de•10/15/26•Bullish

    InflaRx presents kidney data: Needham upgrades InflaRx stock

    InflaRx announced positive kidney data for its drug izicopan, showing at least 90% C5a blockade. Following this, Needham upgraded InflaRx stock from Neutral to Buy. The company...

    ad-hoc-news.de•10/12/26•Bullish

    InflaRx presents kidney data and Needham raises InflaRx stock to Buy

    InflaRx (IFRX) will present new kidney data for its drug izicopan at Kidney Week on October 22, 2026, showcasing its potential in renal indications with promising C5a blockade results. Concurrently...

    AD HOC NEWS•10/5/26•Bullish

    InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026

    InflaRx N.V. (Nasdaq: IFRX) announced it will present late-breaking pre-clinical data on its drug candidate, izicopan, at the American Society of Nephrology’s Kidney Week 2026. The presentation, titled "Izicopan...

    GlobeNewswire•10/2/26•Bullish

    InflaRx N.V. Selected for Late-Breaking Kidney Week 2026 Poster on Izicopan Kidney Disease Models

    InflaRx N.V. has been selected to present a late-breaking poster at the American Society of Nephrology’s Kidney Week 2026, highlighting izicopan, an oral C5a receptor antagonist...

    Quiver Quantitative•10/2/26•Somewhat-Bullish

    IFRX Valuation and Fair Value

    P/E
    -2.4x
    P/FCF
    -6.1x
    P/B
    1.0x
    See GNG's fair value

    IFRX Profitability: Margins, ROIC and FCF

    Operating margin
    352965.0%
    Net margin
    0.0%
    ROE
    -38.5%
    FCF margin
    -70184.0%
    FCF yield
    -16.5%

    IFRX Competitors

    CompanyTicker
    Pyxis Oncology IncPYXS
    Keros Therapeutics IncKROS
    SIGA Technologies IncSIGA
    MacroGenics IncMGNX
    Spok Holdings IncSPOK
    Larimar Therapeutics IncLRMR
    Greenwich Lifesciences IncGLSI
    Owens & Minor IncOMI

    Sector: Healthcare

    IFRX Analyst Ratings

    Consensus
    Buy
    Analysts
    8
    Strong Buy
    0
    Buy
    7
    Hold
    1
    Sell
    0
    Strong Sell
    0

    IFRX Bull Case vs Bear Case

    Bull case

    • 87.5% of IFRX's analyst ratings are Buy or Strong Buy.

    Bear case

    • IFRX beat EPS estimates in 37.5% of its last 8 reported quarters.
    • IFRX's quarterly revenue changed -80.8% year over year.

    IFRX Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    5.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.05
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    3 up, 0 down

    Frequently Asked Questions About IFRX

    Does IFRX pay dividends?

    InflaRx N.V. (IFRX) does not currently pay a regular dividend.

    What is IFRX's market cap?

    InflaRx N.V. (IFRX) has a market capitalization of $219.48M with a current stock price of $1.44.

    Related stocks

    Sector: Healthcare

    All stocks starting with I

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In